Revolutionizing the Way the Body Responds to Injury
Xequel’s proprietary aCT1 peptide technology platform has extensive preclinical and clinical research data to support multiple unique applications and formulations across therapeutic areas. We are committed to developing treatments that address unmet medical needs and revolutionize the way the body responds to injury.
Preclinical
Phase 1
Phase 2
Phase 3
Dermatology – Available for Out-licensing
Cutaneous Radiation Injury (CRI)
Orphan Drug Designation Granted
Ophthalmology — All Rights Globally Out-licensed
Persistent Corneal Epithelial Defects (PCED)
Orphan Drug Designation Pending
Recurrent Corneal Erosions (RCE)
Diabetic
Retinopathy
Pulmonology – Available for Out-licensing
Acute
Lung Injury
(ALI)
Revolutionizing the Way the Body Responds to Injury
Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. Our proprietary aCT1 technology facilitates healing as it stabilizes gap and tight junctions to normalize cell-to-cell signaling, control the flow of fluid within tissues, and reduce harmful inflammation.